Chantal Cossette1, Lisa A Miller2, Qiuji Ye3, Shishir Chourey3, Chintam Nagendra Reddy3, Joshua Rokach3, William S Powell1. 1. Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, Montreal, Quebec, Canada. 2. California National Primate Research Center, University of California, Davis, California, USA. 3. Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, Melbourne, Florida, USA.
Abstract
BACKGROUND AND PURPOSE: The 5-lipoxygenase product, 5-oxo-ETE (5-oxo-6,8,11,14-eicosatetraenoic acid), is a potent chemoattractant for eosinophils and neutrophils. However, little is known about its pathophysiological role because of the lack of a rodent ortholog of the oxoeicosanoid (OXE) receptor. The present study aimed to determine whether the selective OXE receptor antagonist S-Y048 can inhibit allergen-induced pulmonary inflammation in a monkey model of asthma. EXPERIMENTAL APPROACH: Monkeys sensitized to house dust mite antigen (HDM) were treated with either vehicle or S-Y048 prior to challenge with aerosolized HDM, and bronchoalveolar (BAL) fluid was collected 24 h later. After 6 weeks, animals that had initially been treated with vehicle received S-Y048 and vice versa for animals initially treated with S-Y048. Eosinophils and neutrophils in BAL and lung tissue samples were evaluated, as well as mucus-containing cells in bronchi. KEY RESULTS: HDM significantly increased the numbers of eosinophils, neutrophils, and macrophages in BAL fluid 24 h after challenge. These responses were all significantly inhibited by S-Y048, which also reduced the numbers of eosinophils and neutrophils in lung tissue 24 h after challenge with HDM. S-Y048 also significantly reduced the numbers of bronchial epithelial cells staining for mucin and MUC5AC after antigen challenge. CONCLUSION AND IMPLICATIONS: This study provides the first evidence that 5-oxo-ETE may play an important role in inducing allergen-induced pulmonary inflammation and could also be involved in regulating MUC5AC in goblet cells. OXE receptor antagonists such as S-Y048 may useful therapeutic agents in asthma and other eosinophilic as well as neutrophilic diseases.
BACKGROUND AND PURPOSE: The 5-lipoxygenase product, 5-oxo-ETE (5-oxo-6,8,11,14-eicosatetraenoic acid), is a potent chemoattractant for eosinophils and neutrophils. However, little is known about its pathophysiological role because of the lack of a rodent ortholog of the oxoeicosanoid (OXE) receptor. The present study aimed to determine whether the selective OXE receptor antagonist S-Y048 can inhibit allergen-induced pulmonary inflammation in a monkey model of asthma. EXPERIMENTAL APPROACH: Monkeys sensitized to house dust mite antigen (HDM) were treated with either vehicle or S-Y048 prior to challenge with aerosolized HDM, and bronchoalveolar (BAL) fluid was collected 24 h later. After 6 weeks, animals that had initially been treated with vehicle received S-Y048 and vice versa for animals initially treated with S-Y048. Eosinophils and neutrophils in BAL and lung tissue samples were evaluated, as well as mucus-containing cells in bronchi. KEY RESULTS: HDM significantly increased the numbers of eosinophils, neutrophils, and macrophages in BAL fluid 24 h after challenge. These responses were all significantly inhibited by S-Y048, which also reduced the numbers of eosinophils and neutrophils in lung tissue 24 h after challenge with HDM. S-Y048 also significantly reduced the numbers of bronchial epithelial cells staining for mucin and MUC5AC after antigen challenge. CONCLUSION AND IMPLICATIONS: This study provides the first evidence that 5-oxo-ETE may play an important role in inducing allergen-induced pulmonary inflammation and could also be involved in regulating MUC5AC in goblet cells. OXE receptor antagonists such as S-Y048 may useful therapeutic agents in asthma and other eosinophilic as well as neutrophilic diseases.
Authors: E S Schelegle; L J Gershwin; L A Miller; M V Fanucchi; L S Van Winkle; J P Gerriets; W F Walby; A M Omlor; A R Buckpitt; B K Tarkington; V J Wong; J P Joad; K B Pinkerton; R Wu; M J Evans; D M Hyde; C G Plopper Journal: Am J Pathol Date: 2001-01 Impact factor: 4.307
Authors: Gail E Grant; Sylvie Gravel; Julie Guay; Pranav Patel; Bruce D Mazer; Joshua Rokach; William S Powell Journal: Free Radic Biol Med Date: 2011-02-18 Impact factor: 7.376
Authors: Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati Journal: Br J Pharmacol Date: 2014-07-12 Impact factor: 8.739
Authors: J T O'Flaherty; M Kuroki; A B Nixon; J Wijkander; E Yee; S L Lee; P K Smitherman; R L Wykle; L W Daniel Journal: J Immunol Date: 1996-07-01 Impact factor: 5.422
Authors: Carlo Pergola; Gabriele Dodt; Antonietta Rossi; Eva Neunhoeffer; Barbara Lawrenz; Hinnak Northoff; Bengt Samuelsson; Olof Rådmark; Lidia Sautebin; Oliver Werz Journal: Proc Natl Acad Sci U S A Date: 2008-12-08 Impact factor: 11.205